Biotechnology for Healthy Ageing

About this grant

Expected Impact: This Challenge looks to accelerate the development and uptake of clinically validated interventions that target the root cause of multiple age-related morbidities. It will: Deliver biotechnology-based interventions for healthy ageing Accelerate the implementation of personalised care in ageing based on molecular phenotyping​ Provide recommendations for regulatory pathways addressing ageing as a target to inform developers, regulators, and other decision makers​, and Improve citizen literacy on longevity. Expected Outcome: Ambitious proposals put forward under this call will deliver: Proof-of-concepts (TRL3 completed) of biotechnology-based or pharmaceutical interventions that prevents or delays the onset of, or reverts, an age-related disease in a vertebrate model system, based on the hallmarks of ageing, taking into consideration practical challenges of implementing such an intervention Tools to facilitate development or adoption of the interventions above, such as proof-of-concept validation of biomarker signatures or suitable pre-clinical models​, and Approaches to address the shared regulatory hurdles and societal challenges linked to ageing-related interventions, thereby facilitating their adoption​. Portfolio approach The portfolio of projects selected under this Challenge will ensure a coverage of projects developing interventions, biomarkers and NAMs, considering the following guidelines for portfolio composition: Interventions: no more than 5 project... EU contribution per project: EUR 500,000 to EUR 4,000,000 (euros, not converted). UK organisations can apply as the UK is associated to Horizon Europe. Check the topic conditions.